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Bacitracin inhibits fibronectin matrix assembly by mesangial interstitium of the kidney cortex, leading to end-stage
cells in high glucose. renal disease [2]. DN is more common in patients with
Background. Accumulation of mesangial extracellular ma- poor glycemic control [3] and elevated blood glucosetrix is a major characteristic of diabetic nephropathy (DN).
levels are thought to be a major factor initiating the disor-Expression of several extracellular matrix proteins is up-regu-
der, although the mechanisms are poorly understood.lated in human mesangial cells (HMC) cultured in high glucose.
One protein, fibronectin (FN), associates to form an insoluble The mesangial extracellular matrix (ECM) consists of
disulfide-linked matrix and possesses inherent protein-disulfide collagens, laminin, fibronectin (FN), and proteoglycans
isomerase (PDI) activity. Bacitracin is a known PDI inhibitor. [4-6]. The synthesis of several mesangial ECM proteinsWe tested the hypothesis that inhibiting FN-PDI activity with
is increased in diabetes in vivo [7] and in cell culturesbacitracin would disrupt excessive FN-matrix assembly by cul-
maintained in high glucose conditions in vitro [4, 6, 8,tured HMCs grown under high glucose conditions.
Methods. The effect of bacitracin on FN-PDI activity was 9]. In addition, there is also evidence suggesting that
tested using an RNase-refolding assay. High glucose cultures mesangial matrix degradation is decreased in high glu-
of HMC were labeled with 3H-leucine, with and without bacitra-
cose conditions following modulation of the activity ofcin, and 3H-FN immunoprecipitated from the medium and se-
matrix metalloproteinases, plasminogen activators andquential extracts of cell layers to distinguish insoluble FN. FN
transcription was assessed by reverse transcription-polymerase their inhibitors [10]. Together, these factors lead to an
chain reaction (RT-PCR). Pericellular FN-matrix was examined overall increase in mesangial matrix accumulation, which
by immunohistology. compromises glomerular function and is one of the main
Results. Bacitracin inhibited the PDI activity of FN, with
histological hallmarks of DN [11].maximal inhibition at 1.0 mmol/L. Treatment of HMC cultures
Fibronectin, a large glycoprotein consisting of two sim-grown in high glucose with bacitracin brought about changes
in the distribution of newly synthesized FN. With increasing ilar polypeptide chains, is a key component of the mesan-
concentrations of bacitracin there was a significant reduction in gial matrix. Following assembly into a disulfide-linked
the level of FN present as an insoluble matrix of HMC cultures insoluble matrix, FN is important for processes such as
maintained in high glucose, and a corresponding increase in
cell adhesion, migration and differentiation [12]. FN ma-FN in medium. Decreases in FN matrix laid down by HMCs
trix assembly is a highly ordered stepwise process andtreated with different concentrations of bacitracin were seen
by immunohistology. FN mRNA levels were unchanged. many domains along the FN monomer have been shown
Conclusion. PDI inhibition of FN reduces its association into to be important for its formation [13, 14]. Recently, a
an insoluble matrix and potentially provides a new approach to Cys-X-X-Cys motif in the FN twelfth type I repeat hasreduce excessive matrix deposition in DN.
been shown to possess protein-disulfide isomerase (PDI)
activity that is partially cryptic [15]. Since PDI is involved
in disulfide exchange reactions, it has been suggestedDiabetic nephropathy (DN) is a major complication
that this domain is important for FN matrix assembly.of both type I and type II diabetes [1]. Fibrosis occurs
Thus, ability to control the activity of this domain couldin the mesangial compartment of glomeruli and in the
have potential therapeutic implications for disorders
such as DN that are characterized by excessive deposi-
tion of FN in the mesangium [7, 16-18].Key words: protein-disulfide isomerase; extracellular matrix, diabetic
nephropathy, end-stage renal disease, glycoprotein, antibiotic. The macrocyclic dodecapeptide antibiotic bacitracin
inhibits both the oxidative and reductive functions ofReceived for publication March 27, 2001
PDI [19, 20]. Moreover, it inhibits PDI, which is localizedand in revised form June 12, 2001
Accepted for publication June 15, 2001 to the cell surface of mammalian cells and platelets,
where it is catalytically active [21-24]. The mechanism 2001 by the International Society of Nephrology
1756
Weston et al: PDI inhibition reduces FN-matrix assembly 1757
by which bacitracin exerts its inhibitory action is unclear, brought about by the addition of non-denatured RNase
present at a final concentration of 1.4 mol/L.but it is poorly transported into mammalian cells and
even at high concentration it has minimal effects on pro-
Cell cultureliferative capacity [24]. Therefore, this compound could
Human mesangial cells were routinely cultured inbe useful for inhibiting the inherent PDI activity of FN.
RPMI 1640 media, supplemented with 10% (vol/vol) FCSThe aim of the present study was to analyze whether
(Labtech International, Ringmer, East Sussex, UK), 50treatment with bacitracin could reduce levels of insoluble
U/mL penicillin, 50 g/mL streptomycin, 300 g/mL glu-FN matrix deposited by human mesangial cells (HMCs)
tamine, 5 g/mL ITS and 4 mmol/L d-glucose. The cellswhen cultured under high glucose conditions, employing
were maintained in a humidified atmosphere of 5% (vol/this cell-culture system [9] as a model for the situation
vol) CO2:95% air at 37C, and were fed on alternatethat occurs in diabetic nephropathy in vivo.
days with fresh medium. When confluent the cells were
passaged with a 1:3 ratio. Cultures of HMCs between
METHODS passages 6 and 10 were used for the experiments.
Materials
Experimental culture conditions
Bacitracin (lots 49H0625 and 79H1419) was obtained
When used for experiments HMCs were cultured infrom Sigma-Aldrich Chemical Company Ltd. (Poole,
media supplemented with 10% (vol/vol) FCS, which hadUK). As commercially available preparations of bacitra-
previously been depleted of FN. The procedure used tocin are contaminated with a subtilisin-like enzyme [25],
accomplish this was based on the method of Miekka,all experiments were carried out in the presence of prote-
Ingham and Menache [26], and involved passing FCSase-inhibitory concentrations of fetal calf serum (FCS).
over gelatin-Sepharose (Amersham Pharmacia Biotech,The concentrations of bacitracin used in experiments
Amersham, Little Chalfont, UK).relate directly to the compound purchased from Sigma.
Human mesangial cells were removed from tissue cul-All other reagents were purchased from Sigma except
ture flasks with trypsin and seeded at equal density intowhere stated otherwise. HMCs were obtained from Bio-
the desired number of wells on six-well plates (Nalge Nuncwhittaker UK Ltd. (Wokingham, UK).
International, Taastrup, Denmark). After four hours non-
adherent cells were removed by washing and adherentProtein-disulfide isomerase assays
cells were fed with media supplemented with 30 mmol/L
RNase was reduced and denatured essentially as de- d-glucose and either 2 mmol/L, 1 mmol/L, 0.5 mmol/L, or
scribed by Langenbach and Sottile [15]. Briefly, RNase 0.1 mmol/L bacitracin, in addition to control 30 mmol/L
A (30 mg) was dissolved in 1.5 mL of 6 mol/L guanidine- d-glucose and 4 mmol/L d-glucose wells, where no baci-
HCl containing 0.15 mol/L dithiothreitol (DTT) and 0.1 tracin was added. All media also were supplemented
mol/L Tris, pH 8.6. The mixture was left overnight at with l-[4,5-3H]leucine (Amersham Pharmacia Biotech)
room temperature prior to purification of the RNase at a concentration of 8.3 Ci/mL (2 mL per well). The
on an Econo-Pac 10DG column (BioRad Laboratories, cells were left for 48 hours, after which time they were
Richmond, CA, USA), previously equilibrated with 0.1% harvested. Replicate wells, where the cell numbers were
acetic acid. Samples that exhibited peak absorbances at estimated by staining with crystal violet according to the
280 nm were nitrogen-sparged, aliquoted and stored at method of Chana and Wheeler [27], were included.
80C until required. RNase concentrations were esti-
mated using the RNase molar extinction coefficient of Differential extraction of soluble and insoluble FN
9200 M/cm1 at 275 nm. To assess PDI activity, re- from cell layers
duced and denatured RNase (30 mol/L, 400 L/mL) Following treatment, confluent HMC monolayers were
was incubated with FN (1 mol/L), FN and bacitracin fractionated by sequential detergent extractions [28] to
(1 mmol/L, 0.5 mmol/L, 0.1 mmol/L), PDI (1 mol/L), distinguish soluble FN from deoxycholate-insoluble FN.
or PDI and bacitracin (1 mmol/L) in a reaction mixture Briefly, HMC cell layers were scraped into PBS and washed
(500 L) containing 0.1 mol/L Tris, pH 7.4, 1 mmol/L with (a) phosphate-buffered saline (PBS); (b) 3% (vol/
ethylenediaminetetraacetic acid (EDTA) and 5% (vol/ vol) Triton X-100 in PBS; (c) 100 g/mL DNase I in 50
vol) heat-inactivated FCS, for up to 96 hours at 37C. mmol/L Tris-HCl, pH 7.4, containing 10 mmol/L MnCl2;
RNase reactivation was measured by monitoring the ab- and (d) 2% (wt/vol) deoxycholate in 50 mmol/L Tris-
sorbance change at 284 nm of an assay mixture that HCl, pH 8.8, containing 10 mmol/L EDTA. All washes
contained 1.4 mol/L RNase and 0.44 mmol/L cytidine were carried out for three minutes at room temperature.
2:3-cyclic monophosphate in 0.1 mol/L 3-[N-morpholi- FN released during steps a to d was defined as soluble.
no]propane sulfonic acid (MOPS), pH 7.0 [15]. Results FN present in the deoxycholate-insoluble matrix was
solubilized with 1% (wt/vol) sodium dodecyl sulfatewere compared to the absorbance change at 284 nm
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(SDS) and 5 mmol/L DTT in 50 mmol/L Tris-HCl, pH lar weight markers; Amersham Pharmacia Biotech) were
used for comparison.8.2, 5 mmol/L EDTA and 150 mmol/L NaCl. This last
step was performed at 37C for 30 minutes. Complete
RT-PCR analysisMini protease inhibitors (Boehringer Mannheim GmbH,
Total RNA was isolated by the acid guanidinium thio-Mannheim, Germany) were added to the fractions. Pro-
cyanate-phenol-chloroform method [30] using RNAzoltein levels present in the cell-associated fraction were
B according to the manufacturer’s instructions. Two mi-determined using the Coomassie Plus protein assay, fol-
crograms of each RNA sample was converted into cDNAlowing the necessary dilution of the sample (Pierce,
with Superscript II RNase H reverse transcriptase (RT)Rockford, IL, USA).
and random hexamer primers (Gibco BRL, Paisley, Scot-
Immunoprecipitation land, UK) according to the manufacturer’s instructions.
Equal amounts of cDNA were subsequently amplified by3H-Leucine-labeled FN was separated from all other
polymerase chain reaction (PCR) in a 50 L reaction vol-labeled material by immunoprecipitation, prior to liquid
ume containing 1  PCR buffer, 400 mol/L dNTPs, 1.5scintillation counting. Anti-human FN IgG (5 g) was
mmol/L MgCl2, 0.2 mol/L of each specific primer andadded to a portion from each sample, followed by over-
1.25 U Taq DNA polymerase. Conditions for amplificationnight incubation at 4C with constant rotation. Protein-A
were 94C for four minutes, followed by 22 cycles ofSepharose 4B (20 L) was then added to these samples,
94C for one minute, 55C for one minute and 72C forwhich were once more placed at 4C with constant rotation
one minute. A final extension of 72C for ten minutes alsofor two hours. Immune complexes, which were shown
was included. Control amplifications were performed withto contain 95% of the total 3H-FN from each sample,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)were pelleted by centrifugation at 8000 rpm at 4C for
to confirm the use of equal amounts of RNA. The amountfour minutes and the pellets were washed with 1 mL of
of RT reaction used for the amplification (0.5 L) wasice-cold PBS. This procedure was repeated five times.
selected as being non-saturating for the PCR product ofFollowing the final wash, which did not contain radioac-
the genes under investigation after 22 cycles of amplifi-tive counts above background levels, the supernatant
cation. The sequences of the primers used for the ampli-was removed and the pellet resuspended in 500 L of 4
fication of FN mRNA were: (sense) 5-CGAAATCACmol/L guanidine-HCl, 4% (wt/vol) Chaps. The addition
AGCCAGTAG-3 and (antisense) 5-ATCACATCCAof 500 L of 70% ethanol and 3 mL of liquid scintillant
CACGGTAG-3 [31]. The sequences of the primers used(Ecoscint; National Diagnostics, Atlanta, GA, USA) to
for the amplification of GAPDH mRNA were: (sense)
the immunoprecipitated FN fractions was followed by
5-ACCACAGTCCATGCCATCAC-3 and (antisense)
scintillation counting on a Beckman LS6000SC counter. 5-TCCACCACCCTGTTGCTGTA-3. Amplification
products were electrophoresed through 2% (wt/vol) aga-Western blots
rose gels and visualized by ethidium bromide staining.
Samples were mixed with reducing sample buffer [62.5
mmol/L Tris-HCl, 10% (vol/vol) glycerol, 5% (vol/vol) Immunofluorescence
-mercaptoethanol, 2% (wt/vol) SDS, 0.001% (wt/vol) Human mesangial cells (passages 6 to 10) were seeded
bromophenol blue, pH 6.8] and were boiled for three at a sub-confluent density onto sterile coverslips in six-
minutes. When non-reducing conditions were required well tissue culture plates in medium containing 4 mmol/L
the samples were not boiled, and -mercaptoethanol was d-glucose. After 24 hours the cells were maintained with
omitted from the sample buffer. Samples were separated media supplemented with either 4 or 30 mmol/L d-glucose,
by SDS-polyacrylamide gel electrophoresis (PAGE) [29], or with 30 mmol/L d-glucose and 1 mmol/L, 0.5 mmol/L
and proteins were transferred to Immobilon-P polyvi- or 0.1 mmol/L bacitracin. The cells were kept under these
nylidene difluoride (PVDF) membranes (Millipore, Bed- conditions for three to seven days, with medium changes
ford, UK). Non-specific sites were blocked with Tris- every alternate day. The cells were then fixed in 4% (wt/
buffered saline (TBS) containing 0.05% (vol/vol) Tween vol) paraformaldehyde (PFA) for 20 minutes at room
20 and 5% (wt/vol) non-fat milk prior to incubation of temperature, prior to being permeabilized with PBS con-
the membrane with primary antibody, diluted with TBS- taining 0.1% (vol/vol) Triton X-100, for 10 minutes. Non-
Tween containing 0.5% (wt/vol) non-fat milk, overnight specific sites were then blocked with 2 mL of 10% (wt/
at 4C. Incubation with an appropriate secondary anti- vol) Boehringer blocking reagent in 100 mmol/L maleic
body for one hour at room temperature was followed acid, 150 mmol/L NaCl, pH 7.5 (Boehringer Mannheim,
by band visualization with enhanced chemiluminescence Mannheim, Germany), for two hours at room tempera-
(ECL; Amersham Pharmacia Biotech) in accordance ture with gentle rocking. The primary antibody, anti-
with the manufacturer’s instructions. SDS-PAGE molec- human FN (Sigma F3648), was diluted 1/500 in the block-
ing solution and incubated with the cells for 1.5 hoursular weight markers (Rainbow colored protein molecu-
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Fig. 2. Fetal calf serum inhibition of the bacitracin protease contami-
nant. FN (0.1 mol/L) was incubated with 1 mmol/L bacitracin in either
Tris/EDTA buffer with or without 10% or 5% FN-depleted FCS at
37C. Aliquots were removed at time points up to 48 hours and analyzed
for FN by SDS-PAGE and Western blotting. Lanes are: lane 1, 1 mmol/L
Fig. 1. Bacitracin inhibits the protein-disulfide isomerase activity of bacitracin, 10% FN-depleted FCS, 24 hours; lane 2, 48 hours; lane 3,
fibronectin (FN). The ability of FN (1 mol/L) to catalyze the refolding 1 mmol/L bacitracin, 5% FN-depleted FCS, 24 hours; lane 4, 48 hours;
of reduced and denatured RNase () was examined, and compared to lane 5, 1 mmol/L bacitracin, no FCS, 24 hours; lane 6, 48 hours; lane
the level of refolding that occurred in an uncatalyzed reaction (). 7, no bacitracin, 10% FN-depleted FCS, 24 hours; lane 8, 48 hours;
Coincubation with either 0.1 mmol/L (), 0.5 mmol/L () or 1 mmol/L lane 9, 1 mmol/L bacitracin, 10% FCS, 24 hours; lane 10, 48 hours.
() bacitracin inhibited the FN-dependent refolding of RNase. The Incubations up to one week gave the same result.
effect of 1 mmol/L bacitracin () on the activity of native protein-
disulfide isomerase (PDI; 1 mol/L) () was also investigated. RNase
activity is expressed as percent of the activity of non-denatured RNase.
Appropriate controls were carried out. Further details are in the Meth-
ods section. A representative experiment is shown. Each point is the sured by the recovery of enzyme activity (Fig. 1). How-
mean for duplicate cultures. Another experiment gave similar results. ever, the rate of refolding with FN was appreciably lower
than when the same concentration of PDI was used in
the assay. Bacitracin inhibited the PDI activity of intact
at room temperature in a humidified chamber. Washes FN in a concentration-dependent manner. While 0.1
with phosphate-buffered saline (PBS) were followed by mmol/L and 0.5 mmol/L bacitracin reduced the recovery
incubation of the cells with swine anti-rabbit IgG-fluo- of RNase activity by approximately 30% and 60%, re-
rescein isothiocyanate (FITC) conjugate (1/500) for one spectively, after 96 hours, the presence of 1 mmol/L baci-
hour at room temperature. In certain cases incubation tracin completely inhibited the ability of FN to catalyze
with the secondary antibody was followed by incubation RNase refolding. However, 1 mmol/L bacitracin only
with phalloidin-TRITC (50 g/mL) for one hour at room reduced the recovery of RNase activity induced by PDI
temperature. The coverslips were washed once more by 25% (Fig. 1). This difference in the effectiveness of
with PBS prior to mounting with Vectashield mounting bacitracin as an inhibitor of PDI activity could reflect
medium (with or without DAPI; Vector Laboratories differences in the ability of FN and PDI to catalyze
Inc, Burlingame, CA, USA). The cells were inspected RNase refolding in this assay.
in a fluorescence microscope (Olympus Provis) using a The experiments investigating the effect of bacitracin
450 to 490 nm blue excitation filter. Photographs were on the ability of FN to catalyze RNase-refolding were
taken with a mounted camera using 1600 ASA Kodak performed in the presence of FCS since the commercially
color film (Eastman Kodak, Rochester, NY, USA). Con-
available compound has been shown to possess impuri-trol experiments, in which the primary antiserum was
ties, notably a subtilisin-like protease [25]. The contami-omitted, were also carried out.
nating protease was capable of degrading FN (Fig. 2),
even at concentrations of bacitracin as low as 0.1 mmol/L.
RESULTS However FCS, either containing FN or depleted of FN,
Bacitracin inhibits the inherent protein-disulfide was a very effective inhibitor of the protease activity in
isomerase activity of FN concentrations of bacitracin up to 2 mmol/L. Even 5%
(vol/vol) FCS, a concentration that was lower than thatThe activity of RNase is dependent on intramolecular
routinely present in the culture media, completely inhib-disulfide bonding and is lost on reduction and denaturation.
ited FN breakdown (Fig. 2). This inhibition was effectiveRefolding of the denatured enzyme requires protein disul-
over seven days (data not shown), the longest periodfide isomerase. We found that intact FN (1 mol/L) as
used in any subsequent experiments. Moreover, Westernwell as protein disulfide isomerase (1 mol/L) were able
to catalyze the refolding of denatured RNase, as mea- blotting of FN in the refolding assay mixture showed the
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Fig. 3. Effect of bacitracin treatment on FN
levels in the medium and insoluble matrix
fraction of human mesangial cell cultures. Cul-
tures were maintained in either low or high
glucose conditions for 48 hours, with or with-
out various concentrations of bacitracin. Sam-
ples of the media (A) and the deoxycholate-
insoluble matrix fraction (B) were subjected
to SDS-PAGE and Western blotting with an
anti-human FN antibody under non-reducing
(A) and reducing conditions (B). The FN mo-
nomer migrates with a predicted molecular
weight of 250 kD (reduced conditions), while
the dimer migrates at 500 kD (non-reduced
conditions). Loading was such that the volume
of the medium and deoxycholate-insoluble
matrix fractions analyzed was derived from
equal amounts of protein in the cell layer.
Triplicate cultures were analyzed. Represen-
tative results are shown.
molecule to be intact after 96 hours (data not shown). late-insoluble matrix fraction decreased while there was
a corresponding increase of the protein in the mediumFCS did not affect either the activity of native RNase,
or the level of denatured and reduced RNase that re- (Fig. 3). This suggests that bacitracin inhibits the assem-
bly of FN into an insoluble extracellular matrix.folded in uncatalyzed reactions. These observations com-
plement those of Rogelj and colleagues, who demon- To quantitate the effect of bacitracin on the assembly
of FN into the cell layer matrix by cells exposed to highstrated that citrated plasma was an effective inhibitor of
the protease contaminant in bacitracin preparations [25]. glucose, cultures were labeled with 3H-leucine during the
48 hour period following cell attachment. Media were
Bacitracin promotes a redistribution of FN between harvested from the labeled cultures and the cell layers
the medium, soluble and deoxycholate-insoluble extracted with Triton X-100, DNase I, deoxycholate and
matrix fractions SDS/DTT as described in the Methods section. All ex-
tracts were immunoprecipitated with an anti-FN anti-Human mesangial cells were allowed to adhere to tis-
sue culture plastic for four hours and then treated with body and the newly synthesized 3H-FN defined as either
soluble (deoxycholate and preceding fractions) or insolu-different concentrations of bacitracin for the following
48 hours. Wells were stained with crystal-violet at the ble matrix protein (SDS/DTT fraction). The medium was
also immunoprecipitated, enabling the distribution of allend of the experiment to assess cell numbers. These were
not affected by 0.1 to 1.0 mmol/L bacitracin but de- newly synthesized FN in the cultures to be monitored.
The results are shown in Table 1. There was a 1.4-foldcreased by 20% in cultures exposed to 2 mol/L bacitracin
(data not shown). The percentage of adherent cells that increase in total FN synthesis in cultures maintained
in high glucose compared to low glucose conditions, aswere viable, as assessed by trypan-blue staining, was not
appreciably different (9%  2) for the different concen- expected [9]. Statistical analysis using the single-factor
analysis of variance (ANOVAR) showed that this differ-trations of bacitracin examined. These observations indi-
cate that bacitracin is not toxic to cultured human mesan- ence was significant (P 	 0.01). Although there was no
difference in total 3H-FN synthesis between high glucosegial cells in concentrations up to 1.0 mmol/L. This agrees
well with reports by others on the low toxicity of bacitra- cultures maintained in the presence or absence of baci-
tracin there was a dose-dependent change in the distribu-cin to different mammalian cell types, over the range of
concentrations employed in this study [21, 23, 24, 32–34]. tion of the labeled protein between the medium, soluble
and insoluble matrix fractions in the treated culturesSince bacitracin inhibited the PDI activity of FN in
the in vitro assay, we investigated the effect of the com- (Fig. 4, Table 1). As the concentration of bacitracin was
increased, there was a consistent increase in 3H-FN dpmpound on the incorporation of the protein into the extra-
cellular matrix laid down by HMCs cultured in high in the medium and a corresponding decrease in the num-
ber of counts in both the soluble (PBS-Triton, DNAseglucose conditions by SDS-PAGE and Western blotting.
As the concentration of bacitracin increased, the amount and deoxycholate fractions) and matrix (SDS/DTT) frac-
tions. Statistical analysis (ANOVAR) showed that theof FN monomer (250 kD band) present in the deoxycho-
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Table 1. Effect of bacitracin on the synthesis of fibronectin (FN) by cultured human mesangial cells
Bacitracin Glucose 3H-FN radioactivity dpm/1  104 cells
Media  SEM Soluble  SEM Matrix  SEM Total  SEMmmol/L
0 4 151056 47922 42925 2418120 } P 	 0.01
0 30 196991 76824 68422 3421231
P 	 0.05

P 	 0.01

P 	 0.01

NS
0.1 30 202179 75622 67316 3450149
0.5 30 208270 70530 51825 330576
1 30 223362 63821 48713 3358203
2 30 249672 55319 42416 3473199
Cultures were labeled with 3H-leucine while being maintained for 48 hours in low (4 mmol/L) or high (30 mmol/L) glucose conditions with bacitracin at the
concentrations shown. At the end of the experiment the medium, soluble and insoluble matrix fractions were harvested for each culture and immunoprecipitated
with an anti-FN antibody, as described in the text. Results shown are the 3H-FN dpm/1  104 cells for each culture condition and are the means  SEM for three
replicates. Statistical analysis was performed using the single-factor analysis of variance (ANOVAR). Another experiment gave similar results.
Fig. 4. Effect of bacitracin on the distribution
of newly synthesized FN between the medium,
soluble, and insoluble matrix fractions of hu-
man mesangial cell cultures. The 3H-FN dpm
in the medium (), soluble ( ) and insoluble
matrix () compartments of cultures main-
tained under the different conditions (Table
1) are plotted as the percentage of the total
3H-FN for all fractions.
differences in the distribution of 3H-FN dpm among the Bacitracin induces changes in the fibrillar structure of
media (P	 0.05), soluble (P	 0.01) and insoluble matrix FN matrix in human mesangial cell cultures
(P	 0.001) fractions for cell cultures treated with differ- A concentration-dependent decrease in both the total
ent concentrations of bacitracin were significant (Table 1). amount of FN deposited around cells and in the number
Thus, in untreated high glucose cultures the distribution of characteristic FN fibrils formed was detected by immu-
of total 3H-FN between medium, soluble and insoluble nostaining after treating freshly seeded cultures with bac-
matrix fractions was 57.6, 22.4, and 20.0%, while in cul- itracin for up to seven days. The effect of bacitracin after
tures treated with 1.0 mmol/L bacitracin it was 66.5, 19.0 five days of treatment is shown in Figure 6. Despite the
and 14.5%, respectively (P 	 0.01, for the media and decrease in the extent of FN deposition, the cells re-
soluble fractions and P 	 0.001, for the insoluble matrix mained attached to the coverslip. Cells cultured in the
fraction). Treatment of cells cultured in 4 mmol/L glu-
presence of 30 mmol/L glucose alone assembled a morecose with 1.0 mmol/L bacitracin led to a similar redistri-
extensive FN matrix than cells cultured in 4 mmol/L glu-bution of 3H-FN between medium, soluble and insoluble
cose alone (Fig. 6 A and B), which is in agreement withmatrix fractions (data not shown).
the increased levels of insoluble matrix 3H-FN observed
in high glucose cultures after only 48 hours (Table 1).Bacitracin does not affect the level of FN mRNA
Cells exposed to bacitracin concentrations of 0.1, 0.5 orTreatment of cells exposed to high glucose with increas-
1 mmol/L (Fig. 6 C, D, E) exhibited a progressive lossing concentrations of bacitracin over seven days had no
of FN matrix. This was very noticeable at the two highereffect on either the cell number as assessed by crystal-
bacitracin concentrations so that, at 1 mmol/L, very fewviolet staining (data not shown), or on the level of FN
fibrils were observed. At this concentration an increase inmRNA in the mesangial cell cultures, as assessed by
punctate staining was also apparent. Phalloidin stainingreverse transcription-polymerase chain reaction (RT-
PCR) (Fig. 5). indicated that even at those concentrations of bacitracin
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inhibitor of PDI, inhibits the ability of FN to catalyze
the refolding of reduced and denatured RNase. The inhi-
bition was concentration-dependent, and was due solely
to bacitracin and not to the presence of any contaminat-
ing protease. These observations suggested that bacitra-
cin may be able to interfere with FN matrix assembly
by cells in culture and this was confirmed by experiments
showing a concentration dependent decrease in the re-
tention of newly synthesized FN in the soluble and insol-
uble fractions of the cell layer matrix. These decreases
were counterbalanced by an increase in the amount of
FN detected in the culture medium. Indeed, treatment of
high glucose cultures with 1.0 mmol/L bacitracin almost
restored the level of FN in the deoxycholate-insoluble
fraction to that found in cultures maintained with 4 mmol/L
d-glucose alone. The decreased level of FN in the deoxy-
cholate-soluble fraction of high glucose cultures treated
with 1.0 mmol/L bacitracin also is significant, since much
of this pool may become incorporated into the insoluble
matrix with time. Thus, we conclude that bacitracin,Fig. 5. RT-PCR analysis of the effect of bacitracin on the level of fi-
bronectin (FN) mRNA expressed by human mesangial cells (HMCs). while having no effect on the elevated level of FN synthe-
Cell cultures were treated with different concentrations of bacitracin sis in high glucose cultures, is able to markedly reduce
for 7 days, after which total RNA was extracted and 2 g reverse-
the deposition of the protein into the cell matrix. The facttranscribed. The product was amplified by PCR using primers for human
FN, or for GAPDH as a control. The cDNA products were analyzed that similar observations were made with cells cultured in
on a 2% agarose gel and visualized with ethidium bromide. (A) DNA 4 mmol/L glucose and exposed to 1.0 mmol/L bacitracin
markers (lanes 1 and 12). Expression of FN cDNA (639 bp) in cell
provides further evidence that FN PDI activity is funda-cultures maintained in 4 mmol/L (lane 2), or 30 mmol/L glucose (lane 3),
or 30 mmol/L glucose and 0.1 mmol/L (lane 4), or 1.0 mmol/L (lane 5) mental for FN matrix assembly.
bacitracin. RT and PCR control reactions (lanes 6 and 7). Control ampli- Fibronectin matrix assembly is an ordered and tightlyfication of GAPDH cDNA (451 bp) from identical samples (lanes 8 to
regulated process thought to be stabilized through the11). A representative gel is shown. Two other experiments gave the same
result. (B) The cDNA bands were quantified with a scanning densitome- formation of multiple interprotomeric disulfide cross-
ter. The results shown are the ratio of the integrated absorbance of the links [13], although others do not support this view [35].FN band and the corresponding GAPDH band in arbitrary units, and
The data presented in our study support the idea thatare the means  SEM for four separate RT-PCR analyses
interprotomeric disulfide bond formation is important,
since in the presence of bacitracin there was a significant
that led to a very marked reduction in FN matrix, the decrease in matrix assembly, for which the most obvious
characteristic arrangement of the actin cytoskeleton in cause is inhibition of disulfide bond formation by this
the cells was not altered (Fig. 6F). compound [19, 20] during polymerization. Consequently,
more soluble FN is released into the culture medium.
However, there did not appear to be an increase in theDISCUSSION
level of monomer forms of FN in the media of treatedExposure of HMC cultures to high glucose concentra-
cultures, indicating that bacitracin inhibits only interpro-tions (30 mmol/L) leads to up-regulation of FN gene
tomeric and not inter-chain disulfide bond formation.expression and increased FN matrix deposition by these
This is probably because FN is secreted from the cell ascells [9]. Thus, the cell culture system mimics events in
a disulfide-bonded dimer [36]. Bacitracin does not entervivo where excessive matrix deposition in the mesangium
cells [24] and would not have access to the PDI enzymein response to hyperglycemia is one of the major hall-
that catalyzes the formation of interchain disulfide bonds.marks of DN [11]. A targeted reduction of FN matrix
It has been proposed that cryptic sites for FN matrixassembly in cells exposed to high glucose concentrations
assembly may be exposed by tension. FN matrix fibrilscould therefore potentially have application for reducing
are under considerable tension and are highly stretchedmesangial cell fibrosis in DN.
in living cell cultures [37]. Moreover, the inherent PDIA previous study showed that the Cys-X-X-Cys motif
activity of FN is partially cryptic [15]. Thus, bacitracin mayin the 12th type I repeat of FN possesses PDI activity,
exert its effects on stretched FN fibrils, where the PDIalthough a concentration of 4 mol/L FN was required
activity is exposed and fully accessible to the inhibitor.to obtain a level of activity equivalent to that of 1 mol/L
PDI [15]. Moreover, we have shown that bacitracin, an Fibronectin has been shown to regulate the assembly
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Fig. 6. Effect of bacitracin treatment on the
FN matrix laid down by human mesangial cells.
HMCs were seeded onto coverslips, treated
with different concentrations of bacitracin for
5 days, and probed with an anti-FN antibody
(A–E) and with phalloidin-TRITC conjugate
(F ). Details are in the Methods section. (A)
4 mmol/L glucose; (B) 30 mmol/L glucose; (C)
30 mmol/L glucose, 0.1 mmol/L bacitracin;
(D) 30 mmol/L glucose, 0.5 mmol/L bacitracin
(E) 30 mmol/L glucose, 1.0 mmol/L bacitra-
cin; (F) 30 mmol/L glucose, 1.0 mmol/L baci-
tracin. Nuclei visualized with DAPI. Original
magnification; A–D, 50; E, 100; F, 150.
of actin filaments and focal contacts by fibroblasts in ducing excessive matrix deposition in DN, based on in vitro
culture, the control of actin filament assembly being as- cell culture experiments and investigations in vivo with
signed to FN domains III13 and III7-11 [38], and not to animal models [41-46]. All strategies seek to lessen exces-
I12, the domain that possesses PDI activity targeted by sive matrix deposition through the inhibition of some
bacitracin. The mesangial cells remained fully attached upstream factor important for matrix synthesis. For ex-
to the culture wells in 0.1-1.0 mmol/L bacitracin and the ample, such approaches include the reduction of the activ-
actin cytoskeleton was well organized as stress fibers ity of transforming growth factor-1 (TGF-1) [41, 45,
under these conditions. The design of the experiment 46] and its downstream signaling pathway [44], the inhibi-
allowed for cell attachment before exposure to bacitra- tion of the enzyme 3-hydroxy-3-methylglutaryl CoA re-
cin, and these data indicate that such attachments were ductase [43], and the inhibition of albumin glycation [42].
stable once formed and during treatment. However, ad- Inhibition of the ability of FN to associate into an insolu-
dition of bacitracin to cells prior to seeding appreciably ble matrix using a PDI inhibitor may provide an alterna-
reduces their ability to adhere (unpublished observa- tive or complementary approach to these strategies.
tions), suggesting that some FN polymerization may be
necessary for this action. Alternatively, integrin receptor ACKNOWLEDGMENTS
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